Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0321 • ACR Convergence 2022
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
Eugene Krustev¹, John Hanly², Ricky Chin³, Katherine Buhler¹, Francesca S Cardwell⁴, Murray Urowitz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat İnanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵, Marvin Fritzler¹, Ann E Clarke³⁶ and May Choi³⁷, ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ³University of Calgary, Ottawa, ON, Canada, ⁴University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related…
Abstract Number: 0339 • ACR Convergence 2022
Corneal Confocal Microscopy: A Potential Ophthalmic Imaging Biomarker of Neurodegeneration for Systemic Lupus Erythematosus
Miral H.Gharib¹, Georgios Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Al emadi¹, ¹Hamad Medical Corporation, Doha, Qatar, ²Weill Cornell Medicine-Qatar, Research division, Qatar foundation, Doha, Qatar, ³Weill Cornell Medicine-Qatar, Research division, Qatar foundation, institute of cardiovascular sciences, Cardiac center, university of Manchester and NIHR clinical research facility, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms occurring in 80% to 90% of patients with SLE divided…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 0570 • ACR Convergence 2022
Clarifying Misbeliefs About Hydroxychloroquine (HCQ): Developing an Evidence-Based HCQ Benefits vs. Risk Decision Aid (HCQ-SAFE) Per Low Health Literacy Standards
Shivani Garg¹, Sancia Ferguson², Betty Chewning³, Shelby Gomez⁴, Jon Keevil⁵ and Christie Bartels⁶, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine & Public Health, Madison, WI, ³University of Wisconsin, School of Pharmacy, Madison, WI, ⁴UW Health, Stoughton, WI, ⁵NA, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Studies report ~83% of SLE patients discontinue hydroxychloroquine (HCQ) and many report suboptimal shared decision-making with their healthcare team. Moreover, patients report knowledge gaps…
Abstract Number: 0643 • ACR Convergence 2022
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Mary Horton¹, Joanne Nitithalm², Kimberly Taylor³, Laura Trupin⁴, Patricia Katz⁵, Jinoos Yazdany⁶, Maria Dall'Era⁷, Lisa Barcellos⁸, Lindsey Criswell⁹ and Cristina M Lanata¹⁰, ¹NIH/NHGRI, Oakland, CA, ²NIH/NHGRI, Bethesda, MD, ³University of Californi, San Francisco, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶UCSF, San Francisco, CA, ⁷University of California, Division of Rheumatology, San Francisco, CA, ⁸School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, ⁹National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁰NIH/NHGRI, Washington, DC
Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The…
Abstract Number: 0664 • ACR Convergence 2022
Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients
Prathyusha Bachali¹, Erika Hubbard², Kathryn Kingsmore Allison², Yisha He², Amrie Grammer³ and Peter Lipsky², ¹AMPEL BioSolutions, Redmond, WA, ²AMPEL BioSolutions, Charlottesville, VA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Patients with SLE can exhibit considerable clinical heterogeneity. A robust patient stratification approach can help to characterize individual lupus patients more effectively based on…
Abstract Number: 0881 • ACR Convergence 2022
Social Cognitive Correlates of Accelerometer-measured and Self-reported Physical Activity in Persons with Systemic Lupus Erythematosus
Dominique Kinnett-Hopkins¹, Jing Song², Joan Chmiel³, Lauren Bussell¹, Amanda Young¹, Anh Chung³, Daniel Erickson³, Holly Milaeger³, Rosalind Ramsey-Goldman⁴ and Linda Ehrlich-Jones⁵, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Evanston, IL, ³Northwestern University, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ⁵Shirley Ryan AbilityLab, Aurora, IL
Background/Purpose: Evidence suggests that physical activity is a modifiable lifestyle behavior that helps manage the manifestations of systemic lupus erythematosus (SLE). However, persons with SLE…
Abstract Number: 0967 • ACR Convergence 2022
Patterns of Breastfeeding Among Women with and Without Systemic Lupus Erythematosus
Laurel Wolf, Erin Hynd, stephanie Bray, Dulaney Wilson, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Benefits of breastfeeding for maternal and infant health outcomes are well-known. However, many barriers to initiating and maintaining breastfeeding have been identified, particularly for…
Abstract Number: 0989 • ACR Convergence 2022
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Nandita Sarkar¹, Xuguang Hu¹, Nadia Tchao¹, Richard Furie², Alan Kivitz³, Stanley B Cohen⁴ and Kevin Gorski⁵, ¹Amgen Inc., South San Francisco, CA, ²Northwell Health, Great Neck, NY, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Regulatory T cells (Treg) are critical for maintaining self-tolerance and preventing autoimmunity, and IL-2 is essential for their development, survival and suppressive function. Defects…
Abstract Number: 1100 • ACR Convergence 2022
Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States
Jessica Williams¹, Gaobin Bao¹, Charmayne Dunlop-Thomas², Cristina Drenkard², Kim Schofield¹ and S. Sam Lim², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Black patients have higher incidence and severity of systemic lupus erythematosus (SLE) and worse outcomes as compared to White patients, yet Black patients are…
Abstract Number: 1275 • ACR Convergence 2022
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Sana Kang¹, George Gennaoui² and J. Patricia Dhar³, ¹Ascension St John Hospital, Chesterfield, MO, ²Ascension St. John Hospital, St. Clair Shores, MI, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of…
Abstract Number: 1376 • ACR Convergence 2022
Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
Maria Pereira¹, Angela Chun¹, Leigh Stubbs¹ and Marietta De Guzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Eculizumab is a monoclonal antibody that prevents the cleavage of C5, which inhibits the formation of the terminal complement complex. It is approved in…
Abstract Number: 1450 • ACR Convergence 2022
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
Abstract Number: 1469 • ACR Convergence 2022
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Caroline Spitznagel, Fedelis Mutiso, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher prevalence and incidence of herpes zoster (HZ) compared with the general population. Our study was…
Abstract Number: 1591 • ACR Convergence 2022
Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Sandra Sze-jung Wu¹, Gelareh Atefi², Meghan Moynihan³, Kristin Evans³, Liisa Palmer³, Michael Pollack², Christine Dube⁴ and Cassandra Calabrese⁵, ¹AstraZeneca, Hockessin, DE, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Torrington, CT, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].